Prognosis
AstraZeneca Gets Nod From EU for Evusheld and Respiratory Drug
This article is for subscribers only.
The European Union has recommended the use of AstraZeneca Plc’s Evusheld for treating Covid-19, and given the nod to another drug co-developed with Sanofi for preventing respiratory infection from a common virus in young children.
Astra’s antibody cocktail Evusheld had already got the green light from authorities across the world to prevent Covid-19 for people with weakened immune systems. Now, it also has a positive recommendation from an expert panel under the European Medicines Agency for the drug to treat adults and adolescents at risk of progressing to severe Covid.